Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL6396756

Clc1ccc(NC2CCNCC2)cc1Cl.O=C(O)C(F)(F)F

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA1B Q00975 1/20 0.48
P2RX7 Q99572 1/20 0.48
TRPA1 O75762 1/20 0.43
HRH4 Q9H3N8 1/20 0.43
HRH3 Q9Y5N1 1/20 0.43
CDK4 P11802 1/20 0.43
CDK2 P24941 1/20 0.43
CDK5 Q00535 1/20 0.43
GPR6 P46095 1/20 0.41
EPHX1 P07099 2/20 0.41
SLC6A2 P23975 2/20 0.40
SLC6A4 P31645 2/20 0.40
SLC6A3 Q01959 2/20 0.40
HTR6 P50406 4/20 0.40
EPHX2 P34913 1/20 0.40
MEN1 O00255 1/20 0.39
NPC1 O15118 1/20 0.39
LMNA P02545 1/20 0.39
HSP90AA1 P07900 1/20 0.39
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL6156921 0.87 CACNA1B (0.45) CACNA1BP2RX7HRH4HRH3CDK4
SCHEMBL6213417 0.86 P2RX7 (0.49) P2RX7TRPA1SLC6A2SLC6A4SLC6A3
Trifluoroacetic Acid SCHEMBL31706874 0.81 CDK4 (0.44) CDK4CDK2CDK5EPHX1EPHX2
SCHEMBL6156926 0.81 PDK1 (0.44) CACNA1BP2RX7CDK4CDK2CDK5
Trifluoroacetic Acid SCHEMBL4690307 0.80 CACNA1B (0.54) CACNA1BHRH4HRH3CDK4CDK2
Trifluoroacetic Acid SCHEMBL4691138 0.80 CACNA1B (0.54) CACNA1BHRH4HRH3CDK4CDK2
Trifluoroacetic Acid SCHEMBL1936484 0.79 USP30 (0.51) EPHX2MEN1NPC1LMNAHSP90AA1
SCHEMBL12041868 0.78 KDR (0.48) P2RX7HTR6EPHX2MEN1LMNA
Trifluoroacetic Acid SCHEMBL6430601 0.77 CCR5 (0.44) TRPA1GPR6EPHX2MEN1LMNA
SCHEMBL21460294 0.77 SLC6A2 (0.44) P2RX7SLC6A2SLC6A4SLC6A3MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6946478-B2 Compounds ASTRAZENECA AB (SE) 2005-09-20 US disclosed
US-20030134840-A1 Novel compounds ASTRAZENECA AB, A SWEDEN CORPORATION 2003-07-17 US disclosed
US-6518286-B1 Piperidinyl compounds for modulation of immune and inflammatory responses in various diseases and disorders, including asthma ASTRAZENECA AB (SE) 2003-02-11 US disclosed
EP-1165545-A1 NOVEL COMPOUNDS AstraZeneca AB (SE) 2002-01-02 EP disclosed
WO-2000058305-A1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2000-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030134840-A1 Novel compounds RPS4X, RPS4Y1, CYP4B1 CACNA1B 1855/4885P2RX7 1705/4885TRPA1 4325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.